Medication info
Sitagliptin M 50/850 mg tablet (Sitagliptin hydrochloride monohydrate, Metformin hydrochloride, colloidal silicon dioxide)

Sitagliptin M 50/850 mg tablet (Sitagliptin hydrochloride monohydrate, Metformin hydrochloride, colloidal silicon dioxide)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›858.5mg / 1 tablet
Manufacturer / importer
Medica Korea Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTP x 3)]
Approval status
Active

MFDS item code 202200313 · Approved 2022.01.19 · Insurance code 646005590

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The starting dose of this medication should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the starting dose is one tablet of this medication 50/500 mg twice daily. The dose may be increased to one tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Take This Medication). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching to this medication from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The starting dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medication is used with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medication in patients previously treated with another oral antihyperglycemic drug. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medication).

Ingredients

Manufacturer
Medica Korea Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty controlling blood sugar in patients with type 2 diabetes
View approved original text

This medication is administered as an adjunct to diet and exercise to improve blood sugar control in patients with type 2 diabetes. Specifically, it is used in cases where patients have never received diabetes medication treatment, or when sufficient blood sugar control is difficult with monotherapy. It is also administered when blood sugar control with metformin or sitagliptin monotherapy is insufficient or when replacing combination therapy with these two drugs. Additionally, this drug is used in combination with sulfonylurea or thiazolidinedione when blood sugar is not controlled with metformin and sulfonylurea or metformin and thiazolidinedione combinations. It may be administered in combination with insulin if blood sugar control is difficult with insulin and metformin. It effectively improves blood sugar control in various treatment scenarios.

How to take

Adult dose

The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The starting dose of this medication should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the starting dose is one tablet of this medication 50/500 mg twice daily. The dose may be increased to one tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Take This Medication). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching to this medication from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The starting dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medication is used with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medication in patients previously treated with another oral antihyperglycemic drug. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medication).

Precautions

This medication contains sitagliptin and metformin, and there are several precautions to consider while taking it. First, this medication may cause allergic reactions; therefore, if symptoms such as a skin rash, difficulty breathing, or swelling of the face or neck occur, discontinue use immediately and consult with a physician. In addition, serious side effects such as acute pancreatitis, which is inflammation of the pancreas, have been reported. If abdominal pain, nausea, or vomiting occurs during treatment, notify medical personnel immediately. The metformin component may rarely cause lactic acidosis, a serious metabolic abnormality, so if sudden muscle pain, fatigue, difficulty breathing, or abdominal pain occurs, immediate treatment is necessary. This medication should not be administered to patients with moderate or severe renal impairment or severe hepatic dysfunction. Furthermore, treatment with this drug should be temporarily suspended before and after surgery or examinations using iodinated contrast media, and it should be resumed only after normal renal function is confirmed. It is recommended that this medication not be used in pregnant women or breastfeeding mothers. Elderly patients may have decreased renal function, thus regular renal function checks are necessary, and dosage adjustment may be required. During treatment with this medication, alcohol consumption should be avoided, and treatment should be discontinued and a physician consulted in cases of sudden dehydration, severe infections, or cardiovascular problems. When taken in conjunction with other drugs that lower blood sugar, hypoglycemic symptoms may occur, so it is crucial to monitor symptoms closely and adjust drug dosage as necessary. Finally, it is important to have regular checks of blood sugar, renal function, and blood tests to monitor for adverse reactions during treatment with this medication.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 22 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • severe and disabling arthralgia
  • vesiculobullous dermatitis
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • dermatitis
  • loss of appetite
  • weight loss
  • dyspnea
  • unstable angina
  • dizziness
  • acute kidney failure
  • appetite loss
  • gastrointestinal disturbances
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air exposure and kept at room temperature between 1°C and 30°C. Proper storage will help maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.